Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation

Journal of Heart and Lung Transplantation

Volumn 34, Issue 1, 2015, Pages 16-25

  Glanville, Allan R ^a   Aboyoun, Christina ^a   Klepetko, Walter ^b   Reichenspurner, Hermann ^c   Treede, Hendrik ^c   Verschuuren, Erik A ^d   Boehler, Annette ^e   Benden, Christian ^e   Hopkins, Peter ^f   Corris, Paul A ^g  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY HEART CENTER HAMBURG   (Germany)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f THE PRINCE CHARLES HOSPITAL   (Australia)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

BOS; CLAD; cyclosporine C2; everolimus; lung transplantation; monitoring; mycophenolate; sodium

Indexed keywords

CREATININE; CYCLOSPORIN; EVEROLIMUS; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLATE MOFETIL; NONSTEROID ANTIINFLAMMATORY AGENT; RAPAMYCIN;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LEUKOPENIA; LUNG FIBROSIS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; NEPHROTOXICITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VENOUS THROMBOEMBOLISM; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG COMBINATION; FOLLOW UP; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; BRONCHIOLITIS OBLITERANS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84919977042     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2014.06.001     Document Type: Article

References (49)

1. R.D. Yusen, J.D. Christie, and L.B. Edwards The Registry of the International Society for Hart and Lung Transplantation: thirtieth adult lung and heart-lung transplant report - 2013; focus theme: age J Heart Lung Transplant 32 2013 965 978
2. C.M. Burton, J. Carlsen, J. Mortensen, C.B. Andersen, N. Milman, and M. Iversen Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome J Heart Lung Transplant 26 2007 681 686
3. E.P. Trulock Lung transplantation Am J Respir Crit Care Med 155 1997 789 818
4. H. Luckraz, M. Goddard, and K. McNeil Microvascular changes in small airways predispose to obliterative bronchiolitis after lung transplantation J Heart Lung Transplant 23 2004 527 531
5. J.D. Cooper, M. Billingham, and T. Egan A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation J Heart Lung Transplant 12 1993 713 716
6. M. Estenne, J.R. Maurer, and A. Boehler Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria J Heart Lung Transplant 21 2002 297 310
7. A.R. Glanville, C.L. Aboyoun, A. Havryk, M. Plit, S. Rainer, and M.A. Malouf Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation Am J Respir Crit Care Med 177 2008 1033 1040
8. C.M. Burton, M. Iversen, J. Carlsen, and C.B. Andersen Interstitial inflammatory lesions of the pulmonary allograft: a retrospective analysis of 2697 transbronchial biopsies Transplantation 86 2008 811 819
9. J.L. Billings, M.I. Hertz, K. Savik, and C.H. Wendt Respiratory viruses and chronic rejection in lung transplant recipients J Heart Lung Transplant 21 2002 559 566
10. A.P. Khalifah, R.R. Hachem, and M.M. Chakinala Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death Am J Respir Crit Care Med 170 2004 181 187
11. S.M. Palmer, A.P. Miralles, D.N. Howell, S.R. Brazer, V.F. Tapson, and R.D. Davis Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung transplantation Chest 118 2000 1214 1217
12. N. Shah, S.D. Force, and P.O. Mitchell Gastroesophageal reflux disease is associated with an increased rate of acute rejection in lung transplant allografts Transplant Proc 42 2010 2702 2706
13. B.J. King, H. Iyer, A.A. Leidi, and M.R. Carby Gastroesophageal reflux in bronchiolitis obliterans syndrome: a new perspective J Heart Lung Transplant 28 2009 870 875
14. K. Blondeau, V. Mertens, and B.A. Vanaudenaerde Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection Eur Respir J 31 2008 707 713
15. A.R. Glanville Every breath you take Thorax 66 2011 742 743
16. S.E. Verleden, H. Scheers, and T.S. Nawrot Lymphocytic bronchiolitis after lung transplantation is associated with daily changes in air pollution Am J Transplant 12 2012 1831 1838
17. H. Luckraz, M. Goddard, K. McNeil, C. Atkinson, L.D. Sharples, and J. Wallwork Is obliterative bronchiolitis in lung transplantation associated with microvascular damage to small airways? Ann Thorac Surg 82 2006 1212 1218
18. A.E. Frost Bronchiolitis obliterans: the Achilles heel of lung transplantation Verh K Acad Geneeskd Belg 64 2002 303 319 discussion 319-22
19. S. Sundaresan Bronchiolitis obliterans Semin Thorac Cardiovasc Surg 10 1998 221 226
20. R. Vos, B.M. Vanaudenaerde, and S.E. Verleden A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation Eur Respir J 37 2011 164 172
21. B. Nashan Review of the proliferation inhibitor everolimus Expert Opin Investig Drugs 11 2002 1845 1857
22. W. Schuler, R. Sedrani, and S. Cottens SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo Transplantation 64 1997 36 42
23. A. Azzola, A. Havryk, and P. Chhajed Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation Transplantation 77 2004 275 280
24. N.R. Simler, D.C. Howell, and R.P. Marshall The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats Eur Respir J 19 2002 1124 1127
25. U.S. Salminen, P.K. Maasilta, E.I. Taskinen, H.S. Alho, T.S. Ikonen, and A.L. Harjula Prevention of small airway obliteration in a swine heterotopic lung allograft model J Heart Lung Transplant 19 2000 193 206
26. H.J. Eisen, E.M. Tuzcu, and R. Dorent Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients N Engl J Med 349 2003 847 858
27. H.J. Schuurman, S. Cottens, and S. Fuchs SDZ RAD, a new rapamycin derivative: synergism with cyclosporine Transplantation 64 1997 32 35
28. B. Hausen, K. Boeke, G.J. Berry, I.T. Segarra, U. Christians, and R.E. Morris Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine J Heart Lung Transplant 18 1999 150 159
29. B. Hausen, K. Boeke, and G.J. Berry Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment Transplantation 67 1999 956 962
30. B. Hausen, T. Ikonen, and N. Briffa Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability Transplantation 69 2000 76 86
31. L. Potena, P. Prestinenzi, and I.G. Bianchi Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study J Heart Lung Transplant 31 2012 565 570
32. S. Arora, E. Gude, and V. Sigurdardottir Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate J Heart Lung Transplant 31 2012 259 265
33. J.M. Kovarik, H. Eisen, and R. Dorent Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure J Heart Lung Transplant 22 2003 1117 1125
34. H. Tedesco Silva Jr, D. Cibrik, and T. Johnston Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients Am J Transplant 10 2010 1401 1413
35. S. Vitko, H. Tedesco, and J. Eris Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies Am J Transplant 4 2004 626 635
36. J.M. Kovarik, J. Dantal, and G. Civati Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients Am J Transplant 3 2003 1576 1580
37. G.I. Snell, V.G. Valentine, and P. Vitulo Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial Am J Transplant 6 2006 169 177
38. A.R. Glanville, C.L. Aboyoun, J.M. Morton, M. Plit, and M.A. Malouf Cyclosporine C2 target levels and acute cellular rejection after lung transplantation J Heart Lung Transplant 25 2006 928 934
39. D.G. Altman, D. Moher, and K.F. Schulz Improving the reporting of randomised trials: the CONSORT Statement and beyond Stat Med 31 2012 2985 2997
40. K.F. Schulz, D.G. Altman, and D. Moher CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials BMJ 340 2010 c332
41. S.A. Yousem, G.J. Berry, and P.T. Cagle Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group J Heart Lung Transplant 15 1996 1 15
42. S. Stewart, M.C. Fishbein, and G.I. Snell Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection J Heart Lung Transplant 26 2007 1229 1242
43. K. McNeil, A.R. Glanville, and T. Wahlers Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients Transplantation 81 2006 998 1003
44. S. Bhorade, V.N. Ahya, and M.A. Baz Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation Am J Respir Crit Care Med 183 2011 379 387
45. H. Treede, A.R. Glanville, and W. Klepetko Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation J Heart Lung Transplant 31 2012 797 804
46. V.N. Ahya, P.J. McShane, and M.A. Baz Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation J Heart Lung Transplant 30 2011 175 181
47. M.C. Baas, V.E. Gerdes, and I.J. Ten Berge Treatment with everolimus is associated with a procoagulant state Thromb Res 132 2013 307 311
48. J. Groetzner, F. Kur, and F. Spelsberg Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression J Heart Lung Transplant 23 2004 632 638
49. M.B. King-Biggs, J.M. Dunitz, S.J. Park, S. Kay Savik, and M.I. Hertz Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation Transplantation 75 2003 1437 1443